190 related articles for article (PubMed ID: 9423332)
1. [Therapeutic effect of donor leukocyte transfusion in relapsing marrow transplants in Japan].
Shiobara S; Takahasi S; Yabe H; Maruta I; Kodera Y
Rinsho Ketsueki; 1997 Nov; 38(11):1162-9. PubMed ID: 9423332
[TBL] [Abstract][Full Text] [Related]
2. Donor leukocyte infusion for Japanese patients with relapsed leukemia after allogeneic bone marrow transplantation: lower incidence of acute graft-versus-host disease and improved outcome.
Shiobara S; Nakao S; Ueda M; Yamazaki H; Takahashi S; Asano S; Yabe H; Kato S; Imoto S; Maruta A; Yoshida T; Gondo H; Morishima Y; Kodera Y
Bone Marrow Transplant; 2000 Oct; 26(7):769-74. PubMed ID: 11042659
[TBL] [Abstract][Full Text] [Related]
3. Allogeneic cell therapy for relapsed leukemia after bone marrow transplantation with donor peripheral blood lymphocytes.
Slavin S; Naparstek E; Nagler A; Ackerstein A; Kapelushnik J; Or R
Exp Hematol; 1995 Dec; 23(14):1553-62. PubMed ID: 8542946
[TBL] [Abstract][Full Text] [Related]
4. Donor leukocyte infusions for recurrent hematologic malignancies after allogeneic bone marrow transplantation: impact of infused and residual donor T cells.
Verdonck LF; Petersen EJ; Lokhorst HM; Nieuwenhuis HK; Dekker AW; Tilanus MG; de Weger RA
Bone Marrow Transplant; 1998 Dec; 22(11):1057-63. PubMed ID: 9877267
[TBL] [Abstract][Full Text] [Related]
5. Effect of induced GVHD in leukemia patients relapsing after allogeneic bone marrow transplantation: single-center experience of 33 adult patients.
Min CK; Eom KS; Lee S; Kim DW; Lee JW; Min WS; Kim CC
Bone Marrow Transplant; 2001 May; 27(9):999-1005. PubMed ID: 11436112
[TBL] [Abstract][Full Text] [Related]
6. [Treatment of leukemia relapsed after allogenic bone marrow transplantation with donor lymphocyte infusion: report of 11 cases].
Sanz Rodríguez C; Steegmann JL; Granda A; de la Cámara R; Figuera A; Arranz R; Gómez-García de Soria V; Alegre A; Fernández-Rañada JM
Sangre (Barc); 1999 Dec; 44(6):456-63. PubMed ID: 10822760
[TBL] [Abstract][Full Text] [Related]
7. Alpha-interferon with very-low-dose donor lymphocyte infusion for hematologic or cytogenetic relapse of chronic myeloid leukemia induces rapid and durable complete remissions and is associated with acceptable graft-versus-host disease.
Posthuma EF; Marijt EW; Barge RM; van Soest RA; Baas IO; Starrenburg CW; van Zelderen-Bhola SL; Fibbe WE; Smit WM; Willemze R; Falkenburg JH
Biol Blood Marrow Transplant; 2004 Mar; 10(3):204-12. PubMed ID: 14993886
[TBL] [Abstract][Full Text] [Related]
8. Adoptive immunotherapy with donor mononuclear cell infusions to treat relapse of acute leukemia or myelodysplasia after allogeneic bone marrow transplantation.
Porter DL; Roth MS; Lee SJ; McGarigle C; Ferrara JL; Antin JH
Bone Marrow Transplant; 1996 Nov; 18(5):975-80. PubMed ID: 8932854
[TBL] [Abstract][Full Text] [Related]
9. [Successful treatment of recurrent chronic myelogenous leukemia in allogeneic marrow transplant recipient with the donor leukocyte transfusion, without induction of acute graft-versus-host disease].
Yamazaki H; Nakao S; Takamatsu H; Ito T; Ueda M; Shiobara S; Matsuda T
Rinsho Ketsueki; 1995 Jul; 36(7):677-81. PubMed ID: 7563596
[TBL] [Abstract][Full Text] [Related]
10. [Donor leukocyte transfusion as treatment for relapsed chronic myelogenous leukemia after allogeneic bone marrow transplantation].
Itoh T; Hatta Y; Miyajima T; Simojima H; Sawada U; Horie T
Rinsho Ketsueki; 1998 Jun; 39(6):409-15. PubMed ID: 9695667
[TBL] [Abstract][Full Text] [Related]
11. Donor buffy coat infusions for a patient with myelodysplastic syndrome who relapsed following allogeneic bone marrow transplantation.
Tsuzuki M; Maruyama F; Kojima H; Ezaki K; Hirano M
Bone Marrow Transplant; 1995 Sep; 16(3):487-9. PubMed ID: 8535326
[TBL] [Abstract][Full Text] [Related]
12. Induction of a graft-versus-leukemia reaction by cyclosporin A withdrawal as immunotherapy for leukemia relapsing after allogeneic bone marrow transplantation.
Elmaagacli AH; Beelen DW; Trenn G; Schmidt O; Nahler M; Schaefer UW
Bone Marrow Transplant; 1999 Apr; 23(8):771-7. PubMed ID: 10231138
[TBL] [Abstract][Full Text] [Related]
13. T cell-depleted bone marrow transplantation and delayed T cell add-back to control acute GVHD and conserve a graft-versus-leukemia effect.
Barrett AJ; Mavroudis D; Tisdale J; Molldrem J; Clave E; Dunbar C; Cottler-Fox M; Phang S; Carter C; Okunnieff P; Young NS; Read EJ
Bone Marrow Transplant; 1998 Mar; 21(6):543-51. PubMed ID: 9543057
[TBL] [Abstract][Full Text] [Related]
14. Donor T-lymphocyte infusion for unrelated allogeneic bone marrow transplantation with CD3+ T-cell-depleted graft.
Lee CK; deMagalhaes-Silverman M; Hohl RJ; Hayashi M; Buatti J; Wen BC; Schlueter A; Strauss RG; Gingrich RD
Bone Marrow Transplant; 2003 Jan; 31(2):121-8. PubMed ID: 12621494
[TBL] [Abstract][Full Text] [Related]
15. Donor leukocyte infusions for treatment of relapsed acute myeloid leukemia after allogeneic bone marrow transplantation.
Forés R; Díez-Martin JL; Briz M; Cabrera JR; Sanjuán I; Regidor C; Garcia-Talavera J; Fernandez MN
Bone Marrow Transplant; 1996 Mar; 17(3):439-41. PubMed ID: 8704703
[TBL] [Abstract][Full Text] [Related]
16. [The success of lymphocyte infusion as treatment of leukemia recurrence following allogeneic bone marrow transplantation depends on low percentage of patient's own lymphocytes].
Schattenberg AV; van de Wiel-van Kemenade E; Bär BM; Geurts van Kessel AH; van der Maazen RW; de Witte TJ
Ned Tijdschr Geneeskd; 1996 Oct; 140(42):2087-91. PubMed ID: 8965951
[TBL] [Abstract][Full Text] [Related]
17. Adoptive immunotherapy for relapse of chronic myeloid leukemia after allogeneic bone marrow transplant: equal efficacy of lymphocytes from sibling and matched unrelated donors.
van Rhee F; Savage D; Blackwell J; Orchard K; Dazzi F; Lin F; Chase A; Bungey J; Cross NC; Apperley J; Szydlo R; Goldman JM
Bone Marrow Transplant; 1998 May; 21(10):1055-61. PubMed ID: 9632281
[TBL] [Abstract][Full Text] [Related]
18. Unrelated donor marrow transplantation in childhood: a report from the Associazione Italiana Ematologia e Oncologia Pediatrica (AIEOP) and the Gruppo Italiano per il Trapianto Midollo Osseo (GITMO).
Dini G; Cancedda R; Giorgiani G; Porta F; Messina C; Uderzo C; Pession A; Fagioli F; La Nasa G; Arcese W; Pollichieni S; Zecca M; Lanino E; Mazzolari E; Cesaro S; Balduzzi A; Rondelli R; Vassallo E; Cappelli B; Locatelli F;
Haematologica; 2002 Aug; 87(8 Suppl):51-7. PubMed ID: 12412391
[TBL] [Abstract][Full Text] [Related]
19. Prevention of graft-versus-host disease in high risk patients by depletion of CD4+ and reduction of CD8+ lymphocytes in the marrow graft.
Herrera C; Torres A; García-Castellano JM; Roman J; Martin C; Serrano J; Falcon M; Alvarez MA; Gomez P; Martinez F
Bone Marrow Transplant; 1999 Mar; 23(5):443-50. PubMed ID: 10100557
[TBL] [Abstract][Full Text] [Related]
20. Treatment of relapse after allogeneic BMT with donor leukocyte infusions in 16 patients.
Russell LA; Jacobsen N; Heilmann C; Simonsen AC; Christensen LD; Vindelov LL
Bone Marrow Transplant; 1996 Aug; 18(2):411-4. PubMed ID: 8864454
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]